抗幽门螺杆菌感染治疗对急性冠状动脉综合征患者炎症标记物的影响

目的探讨抗幽门螺杆菌感染治疗对急性冠脉综合征(ACS)患者炎症标记物的影响和临床意义。方法将120例有幽门螺杆菌感染的急性冠脉综合征患者随机分成两组。两组均给予ACS常规治疗。治疗组再予奥美拉唑(奥克)20mg、克拉霉素(安吉尔宁)500mg、甲硝唑400mg,每日2次,连服1周。结果治疗后治疗组患者的炎症标记物明显低于对照组。结论抗幽门螺杆菌感染治疗对急性冠脉综合征患者有较好的临床疗效,其机制可能与该类药物能显著降低炎症标记物C-反应蛋白及纤维蛋白原的水平有关。

Effect of inflammation markers in patients with acute coronary syndrome by treating helicobacter pylori infection

[Objective] To investigate the effect of inflammation markers in patients with acute coronary syndrome by treating HP infection and their clinical significance. [Methods] 120 ACS patients with HP infection were felidal randomly into two groups. They were treated in routine way. The trial group was administered with drug of 20 mg of Omeprazole, 500 mg of Clarithromycin and 400 mg of Metronidazole again twice a day, and continued for a week. [Results] The inflammation markers of treatment group in ACS were much lower than the control. [Conclusion] There are much clinical curative effect to treat HP infection in ACS patients. The possible pathogenesis is that the drug reduces remarkably the level of C-reactive protein(CRP) and fibrinogen(FIB).